Aimmune Therapeutics

FDA schedules Aimmune's peanut allergy drug for September expert review
FDA schedules Aimmune's peanut allergy drug for September expert review
Biopharma Dive
Aimmune Therapeutics
peanut allergy
FDA
AR101
Flag link:
4 Blockbuster Drug Launches to Watch in 2019
4 Blockbuster Drug Launches to Watch in 2019
Motley Fool
drug launches
AbbVie
Alexion Pharmaceuticals
Aimmune Therapeutics
Skyrizi
psoriasis
Upadacitinib
rheumatoid arthritis
Ultomiris
PNH
AR101
peanut allergy
Flag link:
Aimmune has its answer on peanut drug's status, but how FDA proceeds still unclear
Aimmune has its answer on peanut drug's status, but how FDA proceeds still unclear
BioSpace
Aimmune Therapeutics
peanut allergy
FDA
AR101
Flag link:
[audio+transcript] 6 Biotech Stocks to Watch Now
[audio+transcript] 6 Biotech Stocks to Watch Now
Motley Fool
Biogen
Bluebird Bio
Global Blood Therapeutics
Aimmune Therapeutics
Vertex Pharmaceuticals
Sarepta Therapeutics
Flag link:
3 Potential New Drugs Held Up by the Shutdown
3 Potential New Drugs Held Up by the Shutdown
Motley Fool
FDA
government shutdown
Aimmune Therapeutics
AR 101
Celgene
fedratinib
Bristol-Myers Squibb
ozanimod
Flag link:
FDA’s Gottlieb Adds Confusion to Aimmune’s Claims of Shutdown Delay
FDA’s Gottlieb Adds Confusion to Aimmune’s Claims of Shutdown Delay
Xconomy
Aimmune Therapeutics
FDA
Scott Gottlieb
government shutdown
Flag link:
Aimmune says shutdown blocks peanut allergy drug review
Aimmune says shutdown blocks peanut allergy drug review
Fierce Biotech
Aimmune Therapeutics
peanut allergy
AR101
FDA
government shutdown
Flag link:
Aimmune's peanut allergy treatment could 'change practice' — with safety challenges and a price anything but peanuts
Aimmune's peanut allergy treatment could 'change practice' — with safety challenges and a price anything but peanuts
Endpoints
Aimmune Therapeutics
AR101
peanut allergy
Flag link:
Nestlé ups its bet on Aimmune’s peanut allergy drug to $276M as NDA filing looms, rivalry intensifies
Nestlé ups its bet on Aimmune’s peanut allergy drug to $276M as NDA filing looms, rivalry intensifies
Endpoints
Nestle
Aimmune Therapeutics
peanut allergy
Flag link: